OncoSec Medical names new chief operating officer
28 July 2020 -

OncoSec Medical Incorporated (NASDAQ:ONCS), a United States-based company developing late-stage intratumoral DNA–based cancer immunotherapies, has named Kellie Malloy Foerter as its new chief operating officer, effective immediately, it was reported on Monday.

In the new role, Foerter will be responsible for the company's finance, engineering and HR functions, and will continue with her leadership of the company's clinical operations, including its two ongoing KEYNOTE clinical trials with lead product candidate, TAVO (interleukin 12 or 'IL-12' plasmid).

Foerter held the position of chief clinical development officer of OncoSec Medical Incorporated, and joined the company in October 2018. Prior to joining the company, she was a senior executive at Syneos Health. She has around three decades of experience in clinical research and started her career at Covance.